|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85 EUR | +0.35% |
|
+7.05% | +41.20% |
| Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
| Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
Laboratorios Farmaceuticos Rovi, S.A. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was EUR 817.7 million compared to EUR 648.68 million a year ago. Net income was EUR 199.67 million compared to EUR 153.08 million a year ago.
Basic earnings per share from continuing operations was EUR 3.73 compared to EUR 2.76 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +41.20% | 4.7B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
LABORATORIOS FARMACEUTICOS ROVI, S.A. 
